Data gathered: November 27
Alternative Data for Xencor
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Google Trends | 19 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 695 | Sign up | Sign up | Sign up |
| Twitter Mentions | 30 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Xencor
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California.
| Price | $25.62 |
| Target Price | Sign up |
| Volume | 251,770 |
| Market Cap | $1.82B |
| Year Range | $15.7 - $26.06 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
 |
Xencor to Participate at Upcoming Investor ConferencesNovember 26 - Yahoo |
 |
Xencor: Plamotamab NHL Data Leads To RA Program AdvancementNovember 21 - SeekingAlpha |
 |
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to TradeNovember 17 - Yahoo |
 |
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden CrossNovember 13 - Yahoo |
 |
Wedbush Predicts Xencor’s FY2024 Earnings (NASDAQ:XNCR)November 12 - ETF Daily News |
 |
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14%November 11 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 11M | 15M | -4M | -45M | -62M | -0.710 |
| Q2 '24 | 15M | 18M | -2.8M | -66M | -59M | -1.070 |
| Q1 '24 | 20M | 14M | 6.5M | -68M | -55M | -1.110 |
| Q4 '23 | 52M | 26M | 26M | -19M | -30M | -0.310 |
| Q3 '23 | 64M | 12M | 52M | -24M | -18M | -0.400 |
Insider Transactions View All
| Dahiyat Bassil I filed to sell 352,615 shares at $24.1. November 25 '24 |
| Dahiyat Bassil I filed to sell 352,615 shares at $24. November 14 '24 |
| Desjarlais John R filed to sell 200,104 shares at $23.5. November 13 '24 |
| Feigal Ellen filed to sell 8,490 shares at $20.7. October 1 '24 |
| Montgomery Alan Bruce filed to sell 9,140 shares at $20.7. October 1 '24 |
Similar companies
Read more about Xencor (XNCR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Xencor?
The Market Cap of Xencor is $1.82B.
What is the current stock price of Xencor?
Currently, the price of one share of Xencor stock is $25.62.
How can I analyze the XNCR stock price chart for investment decisions?
The XNCR stock price chart above provides a comprehensive visual representation of Xencor's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Xencor shares. Our platform offers an up-to-date XNCR stock price chart, along with technical data analysis and alternative data insights.
Does XNCR offer dividends to its shareholders?
As of our latest update, Xencor (XNCR) does not offer dividends to its shareholders. Investors interested in Xencor should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Xencor?
Some of the similar stocks of Xencor are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.